Oxaliplatin Eugia (Oxaliplatin)

Oxaliplatin forms covalent bonds with DNA, creating platinum‑DNA adducts that distort the double helix. This damage blocks DNA replication and transcription, leading to cell‑cycle arrest and apoptosis of rapidly dividing tumour cells, especially those of gastrointestinal origin.

The specific dose of Oxaliplatin Eugia is determined by the treating physician based on factors such as cancer type, treatment protocol, patient weight, renal function and overall health. Clinicians follow established oncology guidelines to calculate the appropriate infusion amount.

Oxaliplatin is classified as contraindicated in pregnancy because it can cross the placenta and cause fetal toxicity. It is also not recommended while breastfeeding, as it may be excreted in milk and harm the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the Oxaliplatin Eugia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oxaliplatin differs from cisplatin and carboplatin by having a distinct diaminocyclohexane carrier ligand, which reduces nephrotoxicity and ototoxicity but increases the risk of peripheral neuropathy. Its efficacy is particularly strong in colorectal cancer, making it a preferred option in FOLFOX‑type regimens.

Oxaliplatin Eugia should be stored below 25 °C in its original packaging, protected from light, moisture and temperature fluctuations. The solution must be inspected for particulate matter before administration and used within the stability period indicated on the label.

The drug is supplied as a sterile solution for intravenous infusion. It is typically infused over 2 hours under medical supervision, often in combination with other chemotherapy agents, and patients are monitored for infusion‑related reactions throughout the administration.

Serious adverse events include severe hypersensitivity reactions, acute neurotoxicity with sudden paresthesia, hemolytic anemia, cardiac arrhythmias and pulmonary toxicity. Prompt recognition and management of these reactions are essential, and patients should be monitored closely during and after infusion.

Oxaliplatin Eugia is contraindicated in patients with known hypersensitivity to platinum compounds, severe pre‑existing neuropathy, uncontrolled cardiac disease, or active infections that could be worsened by myelosuppression. Caution is also advised for individuals with impaired renal or hepatic function.